Alcon Pays $550 Million for Neurotech and Its MacTel Cell Therapy

Alcon has acquired Neurotech Pharmaceuticals for $550 million, the company announced on October 20, 2026. The deal adds revakinagene taroretcel-lwey (Encelto), an encapsulated cell therapy for treating idiopathic macular telangiectasia type 2 (MacTel), to Alcon's retina portfolio.¹ The encapsulated cell therapy is surgically implanted in the eye and is currently available only in the United States. The therapy is the only FDA-approved treatment for MacTel, according to Alcon.¹

"Neurotech's innovative platform sits at the intersection of cell therapy, pharmaceuticals, and surgery, making it a highly complementary addition to our current capabilities and advancing our vision for the future of retinal disease treatment," said David Endicott, CEO of Alcon, in a company press release.¹ "By combining Neurotech's … science and established commercial footprint with Alcon's global reach and clinical expertise, we can help bring this innovation to more patients whose vision is threatened by MacTel."

How does revakinagene taroretcel work?

The therapy is built on Neurotech's encapsulated cell therapy platform, which uses a small, semipermeable capsule containing allogeneic retinal pigment epithelium cells genetically engineered to produce therapeutic proteins.¹ Once implanted intravitreally, the device continuously releases recombinant human ciliary neurotrophic factor, a protein intended to protect retinal cells and reduce the loss of photoreceptors.¹

FDA approved revakinagene taroretcel under a biologics license application in March 2025,² after granting it priority review and orphan drug designation.¹

What did the phase 3 trials show?

Approval was supported by 2 randomized, sham-controlled phase 3 trials, NTMT-03-A and NTMT-03-B. Together they enrolled 228 participants, who were followed for 24 months.³ The primary end point was the rate of ellipsoid zone loss, a marker of photoreceptor degeneration.³

In NTMT-03-A, ellipsoid zone loss was 0.075 mm² in treated eyes vs 0.166 mm² in sham-treated eyes (difference, −0.091 mm²; 95% confidence interval [CI], −0.125 to −0.056; p<.001). In NTMT-03-B, loss was 0.111 mm² vs 0.160 mm² (difference, −0.049 mm²; 95% CI, −0.089 to −0.008; p=.02).³ The National Eye Institute reported that these results corresponded to reductions of 54.8% and 30.6%, respectively. It also reported that reading speed and retinal sensitivity results were mixed across the 2 trials.⁴

What are the deal terms?

Alcon paid $550 million to acquire Neurotech and may be required to make additional contingent payments, including upon the achievement of commercial milestones.¹ The company expects the transaction to be modestly accretive to net sales growth and slightly dilutive to core diluted earnings per share in 2027 and accretive thereafter.¹

Richard Small, CEO of Neurotech, said in the release that Alcon's global scale, commercial capabilities, and scientific expertise will expand and facilitate patient access to the therapy.¹

Why does MacTel need new treatment options?

MacTel is a bilateral, neurodegenerative retinal disease in adults. It causes localized retinal degeneration, progressive loss of central vision, and secondary changes in the retinal blood vessels.¹ Alcon estimates that approximately 25,000 patients in the US have been diagnosed with MacTel and that 2000 to 3000 patients are newly diagnosed each year.¹ Before revakinagene taroretcel, no FDA-approved treatment existed for the disease.¹

"ENCELTO addresses a significant unmet need for MacTel patients," said Dan Miller, MD, PhD, distinguished fellow, research and development, at Alcon.¹

What are the limitations?

Alcon did not disclose the size of potential contingent payments or a timeline for seeking approval outside the US. The US patient estimates are based partly on Alcon's internal claims data analysis on file.¹ In the phase 3 program, the treatment effect on ellipsoid zone loss was smaller in the second trial, and functional outcomes were not consistently significant in both trials.⁴ The therapy also requires surgical implantation, which may affect uptake among patients and retina specialists.

References

1. Alcon. Alcon acquires Neurotech and Encelto, the only FDA-approved treatment for MacTel type 2. Press release. Published October 20, 2026. Accessed October 22, 2026. https://www.businesswire.com/news/home/20261020151062/en/Alcon-Acquires-Neurotech-and-ENCELTO-the-Only-FDA-Approved-Treatment-for-MacTel-Type-2
2. FDA. March 5, 2025 approval letter - Encelto. Accessed October 22, 2026. https://www.fda.gov/media/185733/download
3. Chew EY, Gillies M, Jaffe GJ, et al. Cell-based ciliary neurotrophic factor therapy for macular telangiectasia type 2. NEJM Evid. 2025;4(8):EVIDoa2400481. doi:10.1056/EVIDoa2400481
4. National Eye Institute. Study confirms long-term benefit of implant for blinding eye disease. Published August 8, 2025. Accessed October 22, 2026. https://www.nei.nih.gov/about/news-and-events/news/study-confirms-long-term-benefit-implant-blinding-eye-disease